ILD Biomarker registry, Canada

Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Registration Status: Pending

Objective: Numerous conditions make up the group of disorders called interstitial lung disease (ILD). Most cause progressive scarring of lung tissue that eventually affects your ability to breathe and get enough oxygen into your bloodstream, but beyond this, the disorders vary greatly. Understanding the similarities and differences of these diseases will aid in identifying biomarkers (a specific physical trait used to measure or indicate the effects or progress of a disease or condition) that correlate with disease severity or progression. This biobank will aid access to patient samples in order to conduct research and improve our understanding of ILD.

Registered Biobank Name	ILD Biomarker registry
Biobank Leader	Chris Ryerson
Country	Canada
Email for biobank inquiries	chris.ryerson@hli.ubc.ca
Principal Investigator	Chris Ryerson
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected: